| RESEARCH ARTICLE |
|
| Year : 2021 | Volume
: 53
| Issue : 4 | Page : 270-277 |
Correlation between serum pro inflammatory cytokines and clinical scores of knee osteoarthritic patients using resveratrol as a supplementary therapy with meloxicam
Bushra Hassan Marouf1, Saad Abdulrahman Hussain2, Ziyad Serdar Ali3
1 Department of Pharmacology and Toxicology, College of Pharmacy, University of Sulaimani, Sulaymaniyah, Kurdistan Region, Iraq
2 Department of Pharmacology and Toxicology, Faculty of Pharmacy, Al Rafidain University College, Baghdad, Iraq
3 Department of Rheumatology and Orthopedics, Shar Teaching Hospital, Sulaymaniyah, Kurdistan Region, Iraq
Correspondence Address:
Dr. Bushra Hassan Marouf
Department of Pharmacology and Toxicology, College of Pharmacy, University of Sulaimani, Sulaymaniyah 46001, Kurdistan Region
Iraq
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/ijp.IJP_493_20
OBJECTIVE: The objective of this study was to analyze the associations between the pro-inflammatory markers with the clinical outcomes of knee osteoarthritis (OA) in patients using resveratrol as an add-on treatment with meloxicam.
MATERIALS AND METHODS: This was a double-blind controlled clinical investigation, with 110 eligible patients with OA assigned randomly to receive 15 mg a day meloxicam with either resveratrol 500 mg a day or placebo for 90 days. The standard tools for assessment of pain severity and physical functions were utilized. The tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), and IL-6 in the blood were evaluated. Spearman's correlation coefficient test was used to determine the significance of correlations.
RESULTS: The regression analysis to determine the correlation between reductions of the inflammatory biomarkers with the amelioration of the clinical scores showed a nonsignificant weak correlation between these variables. Total clinical scores of each assessment tool that was used “Knee Injury and OA Outcome Score (KOOS) and WOMAC” displayed a weak and nonsignificant correlation with TNF-α, IL-1β blood level. The Spearman's correlation shows a relatively nonsignificant association between IL-6 levels and KOOS, WOMAC, and Visual Analog Scale scores after incorporating resveratrol as an adjuvant with meloxicam for 90 days.
CONCLUSION: A weak and nonsignificant correlation between serum biomarkers and the clinical outcomes has been suggested in patients with painful knee OA treated with meloxicam and resveratrol.
[FULL TEXT] [PDF]*
|
